Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells.

Cancer letters - 10 Apr 2024

Morimoto Kenji, Yamada Tadaaki, Hirai Soichi, Katayama Yuki, Fukui Sarina, Sawada Ryo, Tachibana Yusuke, Matsui Yohei, Nakamura Ryota, Ishida Masaki, Kawachi Hayato, Kunimasa Kei, Sasaki Takaaki, Nishida Makoto, Furuya Naoki, Watanabe Satoshi, Shiotsu Shinsuke, Nishioka Naoya, Horinaka Mano, Sakai Toshiyuki, Uehara Hisanori, Yano Seiji, Son Bo-Kyung, Tokuda Shinsaku, Takayama Koichi

Abstract excerpt

Recently, novel Kirsten rat sarcoma viral oncogene homolog (KRAS) inhibitors have been clinically developed to treat KRAS G12C-mutated non-small cell lung cancer (NSCLC) patients. However, achieving complete tumor remission is challenging. Therefore, the optimal combined therapeutic intervention with KRAS G12C inhibitors has a potentially crucial role in the clinical outcomes of patients. We investigated the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Share to Signal Transduction

Source

Identifiers

PMID: 38342232
DOI: 10.1016/j.canlet.2024.216692

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells.PMID 38342232Read ↗

Targeting AXL Overcomes Adaptive Resistance to KRAS Inhibition in KRAS-Driven CancerSemantic proximity Read ↗

Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer.Semantic proximity Read ↗

Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Concurrent AXL Inhibition Enhances RAS and ERK Inhibitor Efficacy in <i>KRAS</i> -mutant Pancreatic and Lung CancerSemantic proximity Read ↗

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.Semantic proximity Read ↗

Initial AXL and MCL-1 inhibition contributes to abolishing lazertinib tolerance in EGFR-mutant lung cancer cells.Semantic proximity Read ↗

YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis.Semantic proximity Read ↗

Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC.Semantic proximity Read ↗

SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma.Semantic proximity Read ↗

Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer.Semantic proximity Read ↗

Overcoming Adaptive Resistance to KRAS Inhibitors Through Vertical Pathway Targeting.Semantic proximity Read ↗

Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.